Showing results (171-180 of 234) with videos related to
Sort By:
Pageof 24
JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.JNCI Cancer Spectrum|May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.The Lancet. Oncology|June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trialKarim Fizazi, Ken Herrmann, Bernd J Krause, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.The Lancet. Oncology|November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialChristopher J Logothetis, Ethan Basch, Arturo Molina, et al.The New England Journal of Medicine|June 23, 2021
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerOliver Sartor, Johann de Bono, Kim N Chi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN StudyKim N Chi, Simon Chowdhury, Anders Bjartell, et al.Pageof 24